Nuclidium AG

Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary CuTrace™ platform focuses on creating therapeutic and diagnostic pairs with improved safety and efficacy profiles, benefiting from copper nuclides` advantageous radiation properties and tumor-specific targeting capabilities. By employing diagnostic radionuclide 61Cu and therapeutic radionuclide 67Cu, the platform ensures high-quality imaging and effective anti-tumor therapy, offering lower radiation exposure to patients. The company’s approach allows a higher therapeutic dose per tumor volume and supports tumor imaging at delayed time points, increasing detection rates significantly.